Payment overview · 2025
General Payments
$1,534.19
60 reported records · 19 companies
Healthcare provider profile · identity verified
Ann C Morrill, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITE MARSH, MD · NPI 1104928225
Verified facts
What the public records show
CMS Open Payments records show Ann C Morrill, MD received $1,534.19 in general payments during 2025 across 60 reported records.
Novo Nordisk Inc accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Synthroid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $401.65 | 26.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $197.42 | 12.9% | 13 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $152.29 | 9.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.83 | 9.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $133.56 | 8.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.36 | 4.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.70 | 4.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.87 | 3.6% | 3 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $40.63 | 2.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $39.12 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.36 | 2.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.63 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.64 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.92 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$30.98 | 2.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $26.13 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.77 | 1.0% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $13.51 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.82 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,534.19 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $171.84 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $161.53 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.53 | 8 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $152.29 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $133.56 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $90.66 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.41 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.76 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.36 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.36 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $63.70 | 4 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 47 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 216 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 66 |
| Telmisartan | Telmisartan | 210 | 61 |
| Lisinopril | Lisinopril | 190 | 57 |
| Carvedilol | Carvedilol | 184 | 53 |
| Metformin Hcl | Metformin Hcl | 184 | 58 |
| Ozempic | Semaglutide | 169 | 45 |
| Losartan Potassium | Losartan Potassium | 144 | 45 |
| Omeprazole | Omeprazole | 139 | 48 |
| Mounjaro | Tirzepatide | 133 | 32 |
| Famotidine | Famotidine | 125 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 40 |
| Azithromycin | Azithromycin | 117 | 87 |
| Montelukast Sodium | Montelukast Sodium | 109 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 38 |
| Furosemide | Furosemide | 103 | 36 |
| Tramadol Hcl | Tramadol Hcl | 102 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 34 |
| Liothyronine Sodium | Liothyronine Sodium | 84 | 28 |
| Gabapentin | Gabapentin | 79 | 30 |
| Sertraline Hcl | Sertraline Hcl | 77 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 77 | suppressed |
| Ezetimibe | Ezetimibe | 76 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 23 |
| Potassium Chloride | Potassium Chloride | 65 | 20 |
| Topiramate | Topiramate | 65 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 19 |
| Allopurinol | Allopurinol | 59 | 19 |
| Irbesartan | Irbesartan | 59 | 15 |
| Trazodone Hcl | Trazodone Hcl | 59 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | 17 |
| Diazepam | Diazepam | 54 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 33 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 50 | 22 |
| Meloxicam | Meloxicam | 49 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 26 |
| Synthroid | Levothyroxine Sodium | 47 | 16 |
| Atenolol | Atenolol | 44 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Methylprednisolone | Methylprednisolone | 43 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 17 |
| Eliquis | Apixaban | 40 | 14 |
| Simvastatin | Simvastatin | 40 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Valacyclovir | Valacyclovir Hcl | 37 | 21 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 13 |
| Eszopiclone | Eszopiclone | 35 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 34 |
| Clonidine Hcl | Clonidine Hcl | 34 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nystatin | Nystatin | 33 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 20 |
| Fluconazole | Fluconazole | 32 | 23 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | 13 |
| Amoxicillin | Amoxicillin | 31 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 17 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | 11 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Wegovy | Semaglutide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Imitrex | Sumatriptan Succinate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | 11 |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,534.19 · 60 records | Novo Nordisk Inc | AIRSUPRA, CAMZYOS, Cologuard Collection Kit, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NEFFY, NP Thyroid 60, Ozempic, QULIPTA, REZDIFFRA, Rybelsus, SYNTHROID, Sunosi, TEPEZZA, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error